Severe asthma carries a high burden and often requires biologic therapy targeting type 2 (T2) inflammation. However, treatment response is heterogeneous, and traditional biomarkers, such as blood eosi
Supplementary material Supplementary Material 1: Statistical methods Supplementary Material 2 - Table 1: Data stratified according to bimekizumab dose regimen Supplementary Material 3 - Table 2: Dat
